Brazzelli Valeria, Roveda Elena, Prestinari Francesca, Barbagallo Tania, Bellani Eleonora, Trevisan Valentina, Rona Claudia, Locatelli Franco, Zecca Marco, Borroni Giovanni
Department of Human and Hereditary Pathology, Institute of Dermatology, University of Parvia, Parvia, Italy.
Pediatr Dermatol. 2006 Mar-Apr;23(2):175-8. doi: 10.1111/j.1525-1470.2006.00208.x.
Imatinib mesylate is a drug that has been recently approved for the treatment for chronic myeloid leukemia. It acts as a potent and selective inhibitor of BCR-ABL tyrosine kinase. It also inhibits both c-kit and platelet-derived growth factor receptor tyrosine kinases. Hypopigmentation of the skin in patients receiving this drug has been recently reported. We report a 17-year-old Caucasian patient affected by chronic myeloid leukemia in therapy with imatinib mesylate who developed hypopigmented vitiligo-like patches and generalized lightening of the skin. In order to evaluate the lightening observed clinically, we measured the progressive skin color hypopigmentation by using a colorimeter over several months. The colorimetric evaluation confirmed the generalized and gradual lightening of patient's skin over treatment with imatinib mesylate. We believe that this is the first reported instance of vitiligo-like lesions in a pediatric patient treated with imatinib mesylate, and the second in a Caucasian patient.
甲磺酸伊马替尼是一种最近被批准用于治疗慢性粒细胞白血病的药物。它是一种强效且选择性的BCR-ABL酪氨酸激酶抑制剂。它还抑制c-kit和血小板衍生生长因子受体酪氨酸激酶。最近有报道称接受该药物治疗的患者出现皮肤色素减退。我们报告了一名17岁的白种人慢性粒细胞白血病患者，正在接受甲磺酸伊马替尼治疗，出现了色素减退的白癜风样斑块和全身性皮肤变浅。为了评估临床上观察到的皮肤变浅情况，我们在几个月的时间里使用色度计测量了皮肤颜色逐渐色素减退的情况。色度学评估证实，在甲磺酸伊马替尼治疗期间，患者的皮肤出现了全身性和渐进性变浅。我们认为，这是首例关于接受甲磺酸伊马替尼治疗的儿科患者出现白癜风样病变的报道，也是第二例白种人患者出现这种情况的报道。
